Nintedanib Drug Interactions
Nintedanib has clinically significant interactions primarily through P-glycoprotein (P-gp) and BCRP inhibition, requiring careful management when combined with anticoagulants, while CYP3A4 interactions are minimal and smoking has no clinically relevant effect on its pharmacokinetics.
P-glycoprotein and BCRP Interactions
Nintedanib inhibits P-gp and BCRP transporters in vitro 1, which creates the most clinically important drug interactions:
Direct Oral Anticoagulants (DOACs)
The interaction profile varies significantly by DOAC type:
Rivaroxaban and betrixaban: Contraindicated with nintedanib due to dual BCRP and P-gp substrate properties, leading to excessive drug accumulation and bleeding risk 1
Apixaban: Can be co-administered but requires a 25% dose reduction to compensate for increased exposure via BCRP inhibition 1
Dabigatran: Manageable by administering dabigatran 2 hours before nintedanib in fasted state, which circumvents P-gp-mediated interaction 1
Edoxaban: The preferred DOAC option when anticoagulation is necessary, as the interaction magnitude is weak and no dose adjustment is required 1
Antiplatelet Agents
While concomitant use of antiplatelet agents with nintedanib was not extensively studied in clinical trials, real-world data from the EMPIRE registry showed bleeding incidence remained low (0.25% with nintedanib) even in patients receiving antiplatelet therapy 2. However, monitor closely for bleeding complications, particularly when combining with aspirin or other antiplatelet drugs, as the theoretical bleeding risk exists 3.
CYP3A4 Interactions
Nintedanib has minimal clinically relevant CYP3A4-mediated interactions 4. The drug is primarily metabolized via hydrolytic ester cleavage rather than CYP450 enzymes 4. This means:
- Strong CYP3A4 inhibitors (ketoconazole, itraconazole, clarithromycin, ritonavir) do not require nintedanib dose adjustment
- CYP3A4 inducers (rifampicin, phenytoin, carbamazepine, phenobarbital) do not significantly reduce nintedanib efficacy
- No dose modifications needed when combining with CYP3A4 substrates
This contrasts sharply with other tyrosine kinase inhibitors and represents a practical advantage in polypharmacy situations.
Smoking Effects
Smoking does not require nintedanib dose adjustment 4. While smoking induces CYP1A2 and can affect some drug metabolism 5, nintedanib pharmacokinetics remain within normal inter-patient variability in smokers. The effects of ethnicity, low body weight, older age, and smoking status all fall within the acceptable exposure range 4.
Clinical Monitoring Requirements
Based on ACR/CHEST guidelines 3:
- Liver function tests: Monthly for first 3 months, then every 3 months thereafter
- Monitor for diarrhea and weight loss: Common adverse effects requiring supportive management
- Cardiovascular event monitoring: Particularly in patients with pre-existing cardiovascular disease
Practical Management Algorithm
When anticoagulation is required in a patient on nintedanib:
- First choice: Switch to edoxaban (no dose adjustment needed, minimal interaction)
- Second choice: Use dabigatran with 2-hour separation before nintedanib dosing in fasted state
- Third choice: Use apixaban with 25% dose reduction
- Avoid: Rivaroxaban and betrixaban (contraindicated)
- Alternative: Consider low molecular weight heparin if DOAC options are unsuitable
Common pitfall: Assuming all DOACs behave identically with nintedanib—they do not. The substrate profile (P-gp only vs. P-gp plus BCRP) determines interaction severity.
Key caveat: Real-world bleeding rates remain low (0.29% overall) 2, suggesting that with appropriate monitoring and drug selection, anticoagulation can be safely managed in nintedanib-treated patients. The theoretical bleeding risk should not prevent necessary anticoagulation when proper precautions are taken.